CA2181390A1 - Phospholipid formulations - Google Patents

Phospholipid formulations

Info

Publication number
CA2181390A1
CA2181390A1 CA002181390A CA2181390A CA2181390A1 CA 2181390 A1 CA2181390 A1 CA 2181390A1 CA 002181390 A CA002181390 A CA 002181390A CA 2181390 A CA2181390 A CA 2181390A CA 2181390 A1 CA2181390 A1 CA 2181390A1
Authority
CA
Canada
Prior art keywords
phosphatidylcholine
cellulose
molecular weights
dipalmitoyl
polyoxyethylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002181390A
Other languages
French (fr)
Other versions
CA2181390C (en
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Pankaj Modi
Generex Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pankaj Modi, Generex Pharmaceuticals Inc. filed Critical Pankaj Modi
Publication of CA2181390A1 publication Critical patent/CA2181390A1/en
Application granted granted Critical
Publication of CA2181390C publication Critical patent/CA2181390C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A medicinally active formulation contains i) at least three compounds selected from the group consisting of egg phosphatidylcholine, dilauryl phosphatidylcholine, dimyristoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylcholine, dimyristoyl phosphatidylglycerol, dipalmitoyl phosphatidylglycerol, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, dipalmitoyl phosphatidylethanolamine, distearoyl phosphatidylcholine, brain phosphatidylserine, brain sphingomyelin, cholesterol, cardiolipin, trioctanoin, triolein, soy phosphatidylcholine, poly(adenylic acid), phosphatidylethanolamine, phosphatidyl glycerol, phosphatidyl inositol, sphingosine, cerebroside (glycolipid), and ii) at least one biodegradable polymer selected from the group consisting of copolymers of sucrose and epichlorohydrin having molecular weights of from 70 000 to 400 000, glucose polymers having molecular weights of from 10 000 to 300 000, polyethylene glycols having molecular weights of from 1000 to 100 000, polyvinyl alcohols having molecular weights of from 70 000 to 110 000, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl-methyl cellulose, hydroxypropyl-ethyl cellulose, sodium carboxymethyl cellulose, , starch, crosslinked starch, polyethyleneimine, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, N,N-diethylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters.
The formulation is useful for the production of stable liposomes for delivery of cosmetics, drugs, enzymes, growth factors, hormones, interferons, interleukins, moisturizers, peptides, proteins, and steroids. A variety of administration techniques, e.g.
oral, injection, topical, may be used, depending on the medicinally active ingredient.
CA002181390A 1995-07-18 1996-07-17 Phospholipid formulations Expired - Fee Related CA2181390C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US147395P 1995-07-18 1995-07-18
US60/001,473 1995-07-18

Publications (2)

Publication Number Publication Date
CA2181390A1 true CA2181390A1 (en) 1997-01-19
CA2181390C CA2181390C (en) 2001-04-24

Family

ID=21696188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002181390A Expired - Fee Related CA2181390C (en) 1995-07-18 1996-07-17 Phospholipid formulations

Country Status (1)

Country Link
CA (1) CA2181390C (en)

Cited By (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046287A2 (en) * 1997-04-15 1998-10-22 Uroteq Inc. Drug delivery via therapeutic hydrogels
EP0971699A1 (en) * 1997-01-31 2000-01-19 SkyePharma Inc. Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP1578325A2 (en) * 2002-12-31 2005-09-28 Perricone, Nicholas V., Dr. Stable topical drug delivery compositions
US7875289B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
CN111278441A (en) * 2017-10-11 2020-06-12 巴斯特生物技术 Compositions and methods for treating fibrosis
CN114010801A (en) * 2021-11-16 2022-02-08 上海理工大学 L-ascorbyl palmitate modified small-molecule peptide liposome and preparation and application thereof

Cited By (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
US6228393B1 (en) 1996-04-12 2001-05-08 Uroteq, Inc. Drug delivery via therapeutic hydrogels
US6475516B2 (en) 1996-04-12 2002-11-05 Dicosmo Frank Drug delivery via therapeutic hydrogels
EP0971699A1 (en) * 1997-01-31 2000-01-19 SkyePharma Inc. Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP0971699A4 (en) * 1997-01-31 2006-05-24 Skyepharma Inc Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
EP2322143A1 (en) * 1997-01-31 2011-05-18 Pacira Pharmaceuticals, Inc. Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
WO1998046287A2 (en) * 1997-04-15 1998-10-22 Uroteq Inc. Drug delivery via therapeutic hydrogels
WO1998046287A3 (en) * 1997-04-15 1999-02-11 Univ Toronto Drug delivery via therapeutic hydrogels
US9050248B2 (en) 2002-05-31 2015-06-09 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
US9060925B2 (en) 2002-05-31 2015-06-23 Transdermal Biotechnology, Inc. Methods of delivering stable topical drug compositions
EP1578325A2 (en) * 2002-12-31 2005-09-28 Perricone, Nicholas V., Dr. Stable topical drug delivery compositions
EP1578325A4 (en) * 2002-12-31 2006-09-13 Perricone Nicholas V Dr Stable topical drug delivery compositions
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
US7875289B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US8668937B2 (en) 2011-03-17 2014-03-11 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9937202B2 (en) 2011-03-17 2018-04-10 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9517179B2 (en) 2011-03-17 2016-12-13 Transdermal Biotechnology, Inc. Topical nitric oxide systems and methods of use thereof
US9480707B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9480705B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9198854B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9198853B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US9198930B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9198933B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US9198932B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9198970B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9198931B2 (en) 2012-09-19 2015-12-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9205043B2 (en) 2012-09-19 2015-12-08 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US10034897B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9295638B2 (en) 2012-09-19 2016-03-29 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US10034898B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US10034896B2 (en) 2012-09-19 2018-07-31 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9968635B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US9968634B2 (en) 2012-09-19 2018-05-15 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9950004B2 (en) 2012-09-19 2018-04-24 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9844565B2 (en) 2012-09-19 2017-12-19 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9827266B2 (en) 2012-09-19 2017-11-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9795632B2 (en) 2012-09-19 2017-10-24 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9480710B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US9480708B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9480709B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9480711B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US9480706B2 (en) 2012-09-19 2016-11-01 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9439926B2 (en) 2013-03-13 2016-09-13 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9498535B2 (en) 2013-03-13 2016-11-22 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585829B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585817B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9585931B2 (en) 2013-03-13 2017-03-07 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9597400B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9597401B2 (en) 2013-03-13 2017-03-21 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9636291B2 (en) 2013-03-13 2017-05-02 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9682102B2 (en) 2013-03-13 2017-06-20 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687504B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9694083B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9694029B2 (en) 2013-03-13 2017-07-04 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9700626B2 (en) 2013-03-13 2017-07-11 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9717680B2 (en) 2013-03-13 2017-08-01 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9757467B2 (en) 2013-03-13 2017-09-12 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9827316B2 (en) 2013-03-13 2017-11-28 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9844506B2 (en) 2013-03-13 2017-12-19 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9480642B2 (en) 2013-03-13 2016-11-01 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9872818B2 (en) 2013-03-13 2018-01-23 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9913793B2 (en) 2013-03-13 2018-03-13 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9931370B2 (en) 2013-03-13 2018-04-03 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9937221B2 (en) 2013-03-13 2018-04-10 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9943562B2 (en) 2013-03-13 2018-04-17 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9956290B2 (en) 2013-03-13 2018-05-01 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10028994B2 (en) 2013-03-13 2018-07-24 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US10034914B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US10034828B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US10034944B2 (en) 2013-03-13 2018-07-31 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10064955B2 (en) 2013-03-13 2018-09-04 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US10071117B2 (en) 2013-03-13 2018-09-11 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US10080768B2 (en) 2013-03-13 2018-09-25 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US10155048B2 (en) 2013-03-13 2018-12-18 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US10188603B2 (en) 2013-03-13 2019-01-29 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US10213457B2 (en) 2013-03-13 2019-02-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US10226511B2 (en) 2013-03-13 2019-03-12 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
CN111278441A (en) * 2017-10-11 2020-06-12 巴斯特生物技术 Compositions and methods for treating fibrosis
CN114010801A (en) * 2021-11-16 2022-02-08 上海理工大学 L-ascorbyl palmitate modified small-molecule peptide liposome and preparation and application thereof
CN114010801B (en) * 2021-11-16 2023-09-26 上海理工大学 L-ascorbyl palmitate modified small molecule peptide liposome and preparation and application thereof

Also Published As

Publication number Publication date
CA2181390C (en) 2001-04-24

Similar Documents

Publication Publication Date Title
CA2181390A1 (en) Phospholipid formulations
US5567433A (en) Liposome preparation and material encapsulation method
US6214375B1 (en) Phospholipid formulations
US4673567A (en) Process for preparing liposome composition
EP0460720B1 (en) A method of extruding liposomes
US5330689A (en) Entrapment of water-insoluble compound in alpha tocopherol-based vesicles
US4877561A (en) Method of producing liposome
WO1990014074A1 (en) Improved liposomal formulations of nucleotides and nucleotide analogues
WO1997012602A1 (en) Stimulation of hair follicles
AU6036596A (en) Process for making liposome preparation
CA2407210A1 (en) Liposome drug delivery
KR20090128491A (en) Transpulmonary liposome for controlling drug arrival
KR100496802B1 (en) Pharmaceutical Preparation comprising Lyophilized Liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation
JP3202999B2 (en) Hepatic liposome preparation
CA2079685A1 (en) Synthetic membrane vesicles containing functionally active fusion peptides as drug delivery systems
CA1333360C (en) Tocopherol-based pharmaceutical systems
CA2346016A1 (en) Glucoside paucilamellar vesicles
CA2326348A1 (en) Liposomal bupivacaine compositions and methods of preparation
EP0795325A1 (en) Plasmid entrapping multilamellar liposomes
JPH06345663A (en) Liposome preparation containing vancomycin
CA1330199C (en) Spontaneous vesiculation of multilamellar liposomes
EP1033971B1 (en) Combined chemo-immunotherapy with liposomal drugs and cytokines
JPH10236946A (en) Improved production of double liposome pharmaceutical preparation
JPH04244017A (en) Liposome preparation
CA2181391A1 (en) Controlled Release Tabletted Medicine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed